US20020142304A1
(en)
*
|
2001-03-09 |
2002-10-03 |
Anderson Daniel G. |
Uses and methods of making microarrays of polymeric biomaterials
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
EP2636739B1
(de)
|
2004-03-12 |
2014-12-10 |
Alnylam Pharmaceuticals Inc. |
iRNA-Wirkstoffe für VEGF-Targeting
|
CA2611944A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Massachusetts Institute Of Technology |
Amine-containing lipids and uses thereof
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
DK2068886T3
(da)
*
|
2006-10-03 |
2013-11-18 |
Tekmira Pharmaceuticals Corp |
Lipidholdige præparater
|
US7939505B2
(en)
|
2007-05-04 |
2011-05-10 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
AU2008335202A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor VII gene
|
CA2711240C
(en)
*
|
2008-01-02 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Liver screening method
|
CA2713379A1
(en)
*
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of dsrna targeting the pcsk9 gene
|
CN102014932B
(zh)
|
2008-03-05 |
2015-11-25 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
EP2334793B1
(de)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
|
CN104119242B
(zh)
*
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
CA3018487A1
(en)
|
2008-10-20 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
US8603532B2
(en)
|
2008-10-20 |
2013-12-10 |
Massachusetts Institute Of Technology |
Nanostructures for drug delivery
|
EP2358398A2
(de)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und verfahren
|
US8969353B2
(en)
|
2008-11-07 |
2015-03-03 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
EP2184054A1
(de)
*
|
2008-11-08 |
2010-05-12 |
Lipoxen Technologies Limited |
SiRNA-Abgabe
|
CA3039251C
(en)
*
|
2008-11-10 |
2024-01-09 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
US20120016006A1
(en)
*
|
2008-11-17 |
2012-01-19 |
Alnylam Pharmaceuticals ,Inc. a corporation |
Compositions And Methods For Increasing Cellular Uptake Of RNAi Via SID-1
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
CA2751342C
(en)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
AU2010226434A1
(en)
*
|
2009-03-20 |
2011-10-13 |
Egen, Inc. |
Polyamine derivatives
|
WO2010120385A1
(en)
*
|
2009-04-18 |
2010-10-21 |
Massachusetts Institute Of Technology |
pH SENSITIVE BIODEGRADABLE POLYMERIC PARTICLES FOR DRUG DELIVERY
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
AU2017200272A1
(en)
*
|
2009-05-05 |
2017-02-02 |
Arbutus Biopharma Corporation |
Lipid compositions
|
SG10201911942UA
(en)
*
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
CA2763016C
(en)
|
2009-05-20 |
2018-04-17 |
Eth Zurich |
Targeting micrornas for metabolic disorders
|
WO2010141511A2
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
LT2440183T
(lt)
*
|
2009-06-10 |
2018-08-10 |
Arbutus Biopharma Corporation |
Patobulinta lipido kompozicija
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
MX2011013421A
(es)
|
2009-06-15 |
2012-03-16 |
Alnylam Pharmaceuticals Inc |
Arnds formulado con lipido de direccionamiento del gen pcsk9.
|
WO2011017548A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
DK2474306T3
(en)
|
2009-08-31 |
2017-02-06 |
Nanocarrier Co Ltd |
PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
EP2496238A4
(de)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der transthyretinexpression
|
ES2734973T3
(es)
|
2009-12-01 |
2019-12-13 |
Translate Bio Inc |
Administración de ARNm para el aumento de proteínas y enzimas en enfermedades genéticas humanas
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
CN102905763B
(zh)
*
|
2009-12-23 |
2015-06-17 |
诺华股份有限公司 |
脂质、脂质组合物和使用它们的方法
|
WO2011091065A2
(en)
*
|
2010-01-19 |
2011-07-28 |
Northwestern University |
Synthetic nanostructures including nucleic acids and/or other entities
|
WO2011090965A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids for oligonucleotide delivery
|
WO2011123468A1
(en)
|
2010-03-29 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
EP2555778A4
(de)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
EP3091027B1
(de)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
JP6081910B2
(ja)
|
2010-06-02 |
2017-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
肝線維症治療用組成物および肝線維症の治療法
|
CN103096875B
(zh)
|
2010-06-03 |
2016-08-17 |
阿尔尼拉姆医药品有限公司 |
用于递送活性剂的生物可降解脂质
|
EP2582397A4
(de)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
|
US20130202652A1
(en)
*
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
CN103328500B
(zh)
|
2010-08-04 |
2018-01-26 |
西兹尔生物技术有限公司 |
用于癌症的诊断和治疗的方法和化合物
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP2609135A4
(de)
|
2010-08-26 |
2015-05-20 |
Massachusetts Inst Technology |
Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon
|
WO2012031205A2
(en)
|
2010-09-03 |
2012-03-08 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
JP2014508102A
(ja)
*
|
2010-11-15 |
2014-04-03 |
ライフ テクノロジーズ コーポレーション |
アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
KR101308591B1
(ko)
|
2010-12-30 |
2013-09-13 |
주식회사 삼양바이오팜 |
양이온성 지질을 포함하는 음이온성 약물 전달체 및 그 제조방법
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
PL2691443T3
(pl)
|
2011-03-28 |
2021-08-30 |
Massachusetts Institute Of Technology |
Sprzężone lipomery i ich zastosowania
|
EP3674409A1
(de)
|
2011-03-29 |
2020-07-01 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der tmprss6-genexpression
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
WO2012145374A1
(en)
|
2011-04-19 |
2012-10-26 |
Regulus Therapeutics Inc. |
TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
|
BR112013027187A2
(pt)
|
2011-04-25 |
2017-06-06 |
Regulus Therapeutics Inc |
composto que compreende um oligonucleotídeo modificado complementar a mir-21; oligonucleotídeo modificado; composição farmacêutica; método para diminuir a expressão de colágeno em uma célula; e uso de um composto
|
EP2717893B1
(de)
|
2011-06-08 |
2019-05-08 |
Translate Bio, Inc. |
Lipidnanoteilchenzusammensetzungen und verfahren zur mrna-freisetzung
|
EP3564393A1
(de)
|
2011-06-21 |
2019-11-06 |
Alnylam Pharmaceuticals, Inc. |
Assays und verfahren zur bestimmung der aktivität eines therapeutikums bei einem patienten
|
JP6236385B2
(ja)
|
2011-06-21 |
2017-11-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質c−iii(apoc3)の発現を阻害するための組成物及び方法
|
EP2723758B1
(de)
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verwendungsverfahren dafür
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
EP2723390B1
(de)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP3456317A1
(de)
|
2011-09-27 |
2019-03-20 |
Alnylam Pharmaceuticals, Inc. |
Substituierte di-aliphatic pegylierte lipide
|
ES2911677T3
(es)
|
2011-10-03 |
2022-05-20 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
|
SI3301177T1
(sl)
|
2011-11-18 |
2020-07-31 |
Alnylam Pharmaceuticals, Inc. |
Sredstva RNAi, sestavki in postopki njihove uporabe za zdravljenje s transtiretinom (TTR) povezanih bolezni
|
JP6305344B2
(ja)
*
|
2011-12-07 |
2018-04-04 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性作用物質の送達のための生分解性脂質
|
JP6305343B2
(ja)
|
2011-12-07 |
2018-04-04 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
EP3988104A1
(de)
|
2012-02-24 |
2022-04-27 |
Arbutus Biopharma Corporation |
Kationische trialkyllipide und verfahren zur verwendung davon
|
EP3501550A1
(de)
|
2012-04-02 |
2019-06-26 |
Moderna Therapeutics, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
WO2013158579A1
(en)
|
2012-04-19 |
2013-10-24 |
Merck Sharp & Dohme Corp. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
MX353562B
(es)
|
2012-04-25 |
2018-01-17 |
Regulus Therapeutics Inc |
Compuestos de microarn y metodos de modulacion de la actividad de mir-21.
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
WO2013172358A1
(ja)
*
|
2012-05-14 |
2013-11-21 |
公立大学法人大阪府立大学 |
機能性化合物及びその化合物を含有する分子集合体、並びにそれらを含有する組成物及びキット並びにそれらの使用
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
JP6574383B2
(ja)
|
2012-12-05 |
2019-09-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
PCSK9iRNA組成物及びその使用方法
|
US20150366997A1
(en)
*
|
2012-12-07 |
2015-12-24 |
Shire Human Genetics Therapies, Inc. |
COMPOSITIONS AND METHODS FOR mRNA DELIVERY
|
WO2014093537A1
(en)
|
2012-12-11 |
2014-06-19 |
Isis Pharmaceuticals, Inc. |
Competitive modulation of micrornas
|
CN105283441B
(zh)
*
|
2013-02-28 |
2018-10-23 |
塔夫茨大学 |
用于递送药剂的二硫化合物
|
EP3467108B1
(de)
|
2013-03-14 |
2024-05-22 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
WO2014153163A1
(en)
|
2013-03-14 |
2014-09-25 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
EP2971010B1
(de)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
IL290953B2
(en)
|
2013-03-14 |
2024-01-01 |
Ethris Gmbh |
CFTR mRNA Assemblies and Related Methods and Uses
|
PL2970974T3
(pl)
|
2013-03-14 |
2018-01-31 |
Alnylam Pharmaceuticals Inc |
Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2992095B1
(de)
|
2013-05-01 |
2019-01-09 |
Regulus Therapeutics Inc. |
Microrna-verbindungen und verfahren zur modulation von mir-122
|
NZ630921A
(en)
|
2013-05-01 |
2017-12-22 |
Regulus Therapeutics Inc |
Compounds and methods for enhanced cellular uptake
|
WO2014179562A1
(en)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
TW201515650A
(zh)
|
2013-05-06 |
2015-05-01 |
艾爾妮蘭製藥公司 |
遞送經脂質調配之核酸分子之劑量及方法
|
US20160082126A1
(en)
*
|
2013-05-13 |
2016-03-24 |
Tufts University |
Nanocomplexes for delivery of saporin
|
AP2015008862A0
(en)
|
2013-05-22 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
MY176712A
(en)
|
2013-05-22 |
2020-08-19 |
Alnylam Pharmaceuticals Inc |
Serpina1 irna compositions and methods of use thereof
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
TWI669393B
(zh)
|
2013-10-02 |
2019-08-21 |
艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
EP3052521A1
(de)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
|
PE20161130A1
(es)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
Composiciones y metodos para inhibir la expresion del gen alas1
|
EP3060258A1
(de)
|
2013-10-22 |
2016-08-31 |
Shire Human Genetic Therapies, Inc. |
Mrna-therapie für phenylketonurie
|
EP3060257B1
(de)
|
2013-10-22 |
2021-02-24 |
Translate Bio, Inc. |
Lipidzusammensetzungen zur verabreichung von mrna
|
MX2016005237A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa.
|
EP3060664B1
(de)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Mirna-verbindungen und verfahren zur modulation der mir-21-aktivität
|
EP3985118A1
(de)
|
2013-11-22 |
2022-04-20 |
MiNA Therapeutics Limited |
Kurzes c/ebp-alpha zur aktivierung von rna-zusammensetzungen und verfahren zur verwendung
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
KR102389968B1
(ko)
|
2014-02-11 |
2022-04-25 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
|
JP2017513931A
(ja)
|
2014-04-03 |
2017-06-01 |
インビクタス オンコロジー ピーヴィティー.リミテッド |
超分子コンビナトリアル治療薬
|
JP6881813B2
(ja)
|
2014-04-23 |
2021-06-02 |
モデルナティーエックス, インコーポレイテッド |
核酸ワクチン
|
CN117402871A
(zh)
|
2014-04-25 |
2024-01-16 |
川斯勒佰尔公司 |
信使rna的纯化方法
|
WO2015179724A1
(en)
|
2014-05-22 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
EP3148552B1
(de)
|
2014-05-30 |
2019-07-31 |
Translate Bio, Inc. |
Biologisch abbaubare lipide zur freisetzung von nukleinsäuren
|
NZ727281A
(en)
|
2014-06-24 |
2024-02-23 |
Translate Bio Inc |
Stereochemically enriched compositions for delivery of nucleic acids
|
SI3766916T1
(sl)
|
2014-06-25 |
2023-01-31 |
Acuitas Therapeutics Inc. |
Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin
|
EP3164379A1
(de)
|
2014-07-02 |
2017-05-10 |
Massachusetts Institute of Technology |
Lipidoide aus polyaminfettsäure und verwendungen davon
|
MX2017001493A
(es)
|
2014-08-07 |
2017-05-09 |
Regulus Therapeutics Inc |
Eleccion de micro acidos ribonucleicos (arn) como diana para trastornos metabolicos.
|
HRP20221055T1
(hr)
|
2014-08-29 |
2022-12-23 |
Alnylam Pharmaceuticals, Inc. |
Patisiran za uporabu u liječenju amiloidoze posredovane transtiretinom
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
MX2017003892A
(es)
|
2014-09-25 |
2018-01-30 |
Cold Spring Harbor Laboratory |
Tratamiento del sindrome de rett.
|
CR20170174A
(es)
|
2014-10-02 |
2017-11-07 |
Protiva Biotherapeutics Inc |
Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
CN113846101A
(zh)
|
2014-11-17 |
2021-12-28 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
EP3329003A2
(de)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
|
CN108138182B
(zh)
|
2015-07-31 |
2022-08-19 |
阿尔尼拉姆医药品有限公司 |
甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
AU2016312530A1
(en)
|
2015-08-24 |
2018-03-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
MA44836A
(fr)
|
2015-08-26 |
2018-07-04 |
Univ Texas |
Procédés de traitement du syndrome polykystique des reins
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
PL3350157T3
(pl)
|
2015-09-17 |
2022-05-16 |
Modernatx, Inc. |
Związki i kompozycje do dostarczania wewnątrzkomórkowego środków terapeutycznych
|
FI3368507T3
(fi)
|
2015-10-28 |
2023-03-21 |
Acuitas Therapeutics Inc |
Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
KR101949453B1
(ko)
*
|
2015-12-30 |
2019-02-18 |
주식회사 삼양바이오팜 |
양이온성 지질의 선택적 합성 방법
|
US10836706B2
(en)
|
2016-02-24 |
2020-11-17 |
Rutgers, The State University Of New Jersey |
Bacterial efflux pump inhibitors
|
JP6994140B2
(ja)
|
2016-03-03 |
2022-02-03 |
ユニバーシティ オブ マサチューセッツ |
非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖dna
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
BR112018073683A2
(pt)
|
2016-05-18 |
2019-02-26 |
Modernatx, Inc. |
polinucleotídeos codificadores de relaxina
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
CA3034681A1
(en)
|
2016-06-30 |
2018-01-04 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger rna
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和***
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
EP3548005A4
(de)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
Exosome zur ausgabe von therapeutischen wirkstoffen
|
CN110225747A
(zh)
|
2016-12-05 |
2019-09-10 |
莱古路斯治疗法股份有限公司 |
用于治疗多囊肾病的方法
|
US20200165606A1
(en)
|
2016-12-05 |
2020-05-28 |
Regulus Therapeutics, Inc. |
Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
EA201991747A1
(ru)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
|
BR112019018691A2
(pt)
|
2017-03-10 |
2020-04-07 |
Univ Rutgers |
derivados de indol como inibidores de bomba de efluxo
|
US11938114B2
(en)
|
2017-03-10 |
2024-03-26 |
Rutgers, The State University Of New Jersey |
Bacterial efflux pump inhibitors
|
WO2018165612A1
(en)
|
2017-03-10 |
2018-09-13 |
Rutgers, The State University Of New Jersey |
Bacterial efflux pump inhibitors
|
DK3596042T3
(da)
|
2017-03-15 |
2022-04-11 |
Modernatx Inc |
Krystalformer af aminolipider
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
US20200405639A1
(en)
|
2017-04-14 |
2020-12-31 |
The Broad Institute, Inc. |
Novel delivery of large payloads
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
WO2018218192A1
(en)
|
2017-05-26 |
2018-11-29 |
Rutgers, The State University Of New Jersey |
Bacterial efflux pump inhibitors
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
WO2019005841A1
(en)
|
2017-06-26 |
2019-01-03 |
Rutgers, The State University Of New Jersey |
THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
TW201920669A
(zh)
|
2017-09-08 |
2019-06-01 |
英商美納治療公司 |
HNF4a saRNA組成物和使用方法
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
CA3085442A1
(en)
|
2017-09-19 |
2019-03-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US20190175560A1
(en)
|
2017-12-01 |
2019-06-13 |
Shepherd Therapeutics, Inc. |
Mebendazole cancer therapies and methods of use
|
WO2019126739A1
(en)
|
2017-12-21 |
2019-06-27 |
Shepherd Therapeutics, Inc. |
Pyrvinium pamoate anti-cancer therapies
|
US10968257B2
(en)
|
2018-04-03 |
2021-04-06 |
The Broad Institute, Inc. |
Target recognition motifs and uses thereof
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
WO2020037125A1
(en)
|
2018-08-16 |
2020-02-20 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
EP4218722A3
(de)
|
2018-10-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
US20220096517A1
(en)
|
2018-11-13 |
2022-03-31 |
Regulus Therapeutics Inc. |
MicroRNA Compounds and Methods for Modulating MIR-10B Activity
|
CN109432504B
(zh)
*
|
2018-11-27 |
2021-11-16 |
中国人民解放军总医院第四医学中心 |
一种成骨基因干预功能材料及其制备方法
|
EP3898977A1
(de)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Zusammensetzungen und verfahren zur behandlung von kcnt1-assoziierten erkrankungen
|
CN113474328A
(zh)
|
2019-01-11 |
2021-10-01 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
US20220154222A1
(en)
|
2019-03-14 |
2022-05-19 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
JPWO2021020412A1
(de)
|
2019-07-30 |
2021-02-04 |
|
|
EP4013870A1
(de)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
|
AU2020343255A1
(en)
|
2019-09-03 |
2022-03-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
CN114929205A
(zh)
*
|
2019-09-06 |
2022-08-19 |
世代生物公司 |
包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
|
CN114728887A
(zh)
|
2019-09-19 |
2022-07-08 |
摩登纳特斯有限公司 |
用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
|
WO2021061707A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
EP4041894A1
(de)
|
2019-09-23 |
2022-08-17 |
Omega Therapeutics, Inc. |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULIERUNG DER HEPATOZYTENNUKLEARFAKTOR-4-ALPHA (HNF4a)-GENEXPRESSION
|
EP4038189A1
(de)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
EP4051795A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
BR112022011417A2
(pt)
|
2019-12-13 |
2022-08-30 |
Alnylam Pharmaceuticals Inc |
Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
|
MX2022009410A
(es)
*
|
2020-01-31 |
2022-10-18 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
AU2021234302A1
(en)
|
2020-03-11 |
2022-11-10 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
CN115667531A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒DNA载体和其用于表达戈谢(Gaucher)治疗剂的用途
|
CA3172572A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
MX2022012561A
(es)
|
2020-04-07 |
2022-11-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
|
AU2021263554A1
(en)
|
2020-04-27 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein E (APOE) iRNA agent compositions and methods of use thereof
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
IL299925A
(en)
|
2020-07-27 |
2023-03-01 |
Anjarium Biosciences Ag |
Compounds of DNA molecules, methods for their preparation and methods of using them
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4291654A2
(de)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
CA3214137A1
(en)
|
2021-03-26 |
2022-09-29 |
Mina Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
AR125230A1
(es)
|
2021-03-29 |
2023-06-28 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
EP4326860A1
(de)
|
2021-04-20 |
2024-02-28 |
Anjarium Biosciences AG |
Zusammensetzungen von dna-molekülen zur codierung von amylo-alpha-1,6-glucosidase, 4-alpha-glucanotransferase, verfahren zur herstellung davon und verfahren zur verwendung davon
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
US20240226324A1
(en)
|
2021-04-27 |
2024-07-11 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022241723A1
(zh)
*
|
2021-05-20 |
2022-11-24 |
北京理工大学 |
化合物、脂质体及其用途
|
WO2022256290A2
(en)
|
2021-06-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
AR126675A1
(es)
|
2021-08-03 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
EP4402121A1
(de)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclische lipide und verfahren zur verwendung davon
|
WO2023060238A2
(en)
|
2021-10-08 |
2023-04-13 |
Regulus Therapeutics Inc. |
Methods and compositions for avoiding off-target effects
|
TW202320808A
(zh)
|
2021-10-08 |
2023-06-01 |
美商雷格勒斯治療公司 |
用於治療多囊性腎病之方法及組合物
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
CA3236235A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023092102A1
(en)
|
2021-11-19 |
2023-05-25 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
CA3242118A1
(en)
|
2021-12-22 |
2023-06-29 |
Alfica Sehgal |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
KR20230096311A
(ko)
*
|
2021-12-23 |
2023-06-30 |
주식회사 삼양홀딩스 |
약물의 폐 전달용 나노입자 조성물
|
KR20230096312A
(ko)
*
|
2021-12-23 |
2023-06-30 |
주식회사 삼양홀딩스 |
약물 전달용 지질 및 이를 포함하는 나노입자, 및 이 나노입자를 포함하는 약물 전달용 조성물
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023143601A1
(zh)
*
|
2022-01-30 |
2023-08-03 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
WO2023143591A1
(zh)
*
|
2022-01-30 |
2023-08-03 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
US20240002857A1
(en)
|
2022-05-09 |
2024-01-04 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
CN117247359A
(zh)
*
|
2022-06-09 |
2023-12-19 |
中国科学院广州生物医药与健康研究院 |
一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024031101A1
(en)
|
2022-08-05 |
2024-02-08 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024064910A1
(en)
|
2022-09-23 |
2024-03-28 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
US20240175026A1
(en)
|
2022-10-14 |
2024-05-30 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
WO2024119039A2
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticles and uses thereof
|
WO2024119051A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2024125469A1
(en)
*
|
2022-12-12 |
2024-06-20 |
Starna Therapeutics |
Novel compounds and use thereof for targeted delivery
|
WO2024137590A2
(en)
|
2022-12-19 |
2024-06-27 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting cfb and uses thereof
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|